Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Frontline Alectinib Outperforms Crizotinib in Asian Patients With ALK+ NSCLC
Asian patients with untreated ALK-positive advanced NSCLC lived significantly longer without disease progression if they received the next-generation tyrosine kinase inhibitor alectinib instead of crizotinib as initial therapy.
Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer
First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.
Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Nonsquamous NSCLC
October 22nd 2018The first-line triplet of atezolizumab, carboplatin, and nab-paclitaxel was associated with a statistically significant improvement in both progression-free and overall survival compared with chemotherapy alone in patients with stage IV nonsquamous NSCLC, according to results from the phase III IMpower130 trial.
Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma
Long-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treated with adjuvant dabrafenib plus trametinib.
Pembrolizumab Improves OS, but Not PFS and ORR in Frontline HNSCC
October 22nd 2018Frontline pembrolizumab monotherapy showed an improvement in overall survival and duration of response versus standard therapy in patients with PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma; however, there was not a similar improvement in progression-free survival or overall response rate with the PD-1 inhibitor.
Atezolizumab Plus Bevacizumab Shows Durable Activity in Advanced HCC
The combination of the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab showed promising and durable antitumor activity in a phase Ib study of patients with advanced hepatocellular carcinoma.
Rucaparib Responses Reached in Nearly Half of Men With BRCA+ mCRPC
Preliminary data from the ongoing phase II TRITON2 trial demonstrated a 44% confirmed objective response rate by investigator assessment among evaluable men with BRCA1/2-mutated metastatic castration-resistant prostate cancer who were treated with the PARP inhibitor rucaparib.
Higher Dose of Ipilimumab Added to Nivolumab Effective in Bladder Cancer
October 22nd 2018Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.
Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer
October 22nd 2018The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.
Tepotinib Plus Gefitinib Improves PFS in MET+ EGFR-Mutant NSCLC
October 21st 2018The combination of tepotinib plus gefitinib improved progression-free survival and overall response versus chemotherapy in patients with MET mutated EGFR-positive non–small cell lung cancer resistant to prior EGFR TKI therapy.
Radiotherapy Raised to New Standard in Newly Diagnosed Prostate Cancer With Low Metastatic Burden
When added to standard of care therapy, radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden.
Avelumab/Axitinib Nearly Doubles PFS, ORR in Frontline RCC
October 21st 2018The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.
Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer
The PARP inhibitor niraparib has shown durable clinical activity in later lines of therapy in patients with relapsed ovarian cancer who have BRCA mutations, according to a posthoc analysis of the phase II QUADRA study.
Alpelisib Combo Nearly Doubles PFS in PIK3CA-Mutant Breast Cancer
The addition of the PI3K inhibitor alpelisib to fulvestrant nearly doubled median progression-free survival compared with the endocrine therapy alone in patients with HR-positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.
OS Benefit Confirmed With Palbociclib Combo in Pretreated HR+/HER2- Breast Cancer
October 21st 2018The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.
Dr. Cristofanilli on Survival Findings From the PALOMA-3 Trial
October 20th 2018Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.
Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer
October 20th 2018Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.
